Hospitals Show Quality Gains in Joint Commission Report – Becker’s Hospital Review


WTHI

Hospitals Show Quality Gains in Joint Commission Report
Becker’s Hospital Review
Hospitals continue to show improvements in quality measures for heart attacks, pneumonia, surgery and children's asthma but there still are a few areas for
Quality of Care at U.S. Hospitals Shows ImprovementBusinessWeek
Quality of care gets better in US hospitalsHealthcare Digital (press release)
Quality of care up at US hospitals, report saysThe Associated Press
Marketwire (press release) –DailyFinance
all 263 news articles »

View full post on asthma – Google News

Life-threatening Asthma Attacks in Children Cut Dramatically-Study Shows – News Hawks Review


TopNews Arab Emirates

Life-threatening Asthma Attacks in Children Cut Dramatically-Study Shows
News Hawks Review
Serious asthma attacks among children decreased by 18% per year. The cause of this dramatic reduction is a 2006 public smoking ban in Scotland.
Smoking ban benefits children with asthmaeMaxHealth
Smoking ban cuts asthma attacks in Scottish childrenMadeForMums (blog)
Smoking Ban Good For Kids, Freezing Your Fatmyfoxny.com
ModernMedicine –WGME –121doc
all 323 news articles »

View full post on asthma – Google News

Report shows high costs of chronic medical conditions in Michigan – Michigan Business Review – MLive.com

Report shows high costs of chronic medical conditions in Michigan
Michigan Business Review – MLive.com
The study examined the costs of treating people with diabetes, asthma, mental disorders, chronic obstructive lung disease, osteoarthritis, coronary artery
Chronic diseases drive high health care costs in Michigan, report findsCrain’s Detroit Business
Report: Health issues are costly for MichiganDetroit Free Press

all 4 news articles »

View full post on asthma – Google News

FDA accepts to review sNDA for SPRYCEL for treating adult patients with CML

FDA accepts to review sNDA for SPRYCEL for treating adult patients with CML
Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. today announced that the U.S. Food and Drug Administration has accepted for filing and review the supplemental New Drug Application for SPRYCEL (dasatinib) for the treatment of adult patients with newly diagnosed chronic myeloid leukemia in chronic phase.

Read more on News-Medical-Net